以第一作者在Blood,Journal of Hematology & Oncology,Journal of Nucleic Acids Research,Pediatric Blood Cancer,elife等杂志发表多篇SCI论文及国家核心期刊论文
[CML] Cancer Drugs On The Way, But Who Pays?Rob [CML] pcr test resultsskink1100 [CML] Lymph Node QuestionLibby Scrivner [CML] Lymph Node Questionlscrivy [CML] Myelodysplasic syndromes: A comprehensive reviewRob [CML] DRUG MAKERS AIM FOR A BULL'S-EYE - Firms such as Bristol-Myers Squi...
[CML] Experimental method delivers assault on blood cancer Rob [CML] It's a sad journey along a fast road to see our parents Rob [CML] Gmail Users Can Now Add CML News Feed At Top Of The Page Rob [CML] Link To CML Clinical Trials Rob [CML] seeking help and input choqol.....
Fresh (<48 h), 4 ml non-leukemic peripheral blood samples (n = 360) were processed and pooled to generate BCR::ABL1 negative lysates with sufficient ABL1 copies (Trizol n = 4, RLT n = 4). BCR::ABL1 negative samples (n = 4) were provided to each ...
Statistical analysis was performed using Student's t-test. Po0.05 was considered statistically significant. Blood Cancer Journal & 2013 Macmillan Publishers Limited RESULTS MR-1 is overexpressed in blast crisis cells and downregulated in PMA-treated cells Our results revealed that MR-1 was ...
Molecular response is monitored by quantitative polymerase chain reaction (qPCR) studies on peripheral blood. It is usually performed at diagnosis, then every 3 months until BCR-ABL1 transcripts are < 0.1%, then every 3-6 months. Definitions are as follows: Early molecular response: BCR-ABL1 ...
941 Defining extrinsic survival pathways in CML progenitor cells Ryan MacKenzie1, Jennifer Snead1, Jonathan VanDyke1, Brian Druker1,2, Michael Deininger1 1Center for Hematologic Malignancies, Oregon Health & Science University Cancer Institute, 2Howard Hughes Medical Institute, 3181 S.W. Sam Jackson...
Clin Cancer Res., 20 (2) (2014), pp. 310-322 View in ScopusGoogle Scholar 2 DM Ross, S Branford, JF Seymour, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study Blood, 122 (4) (2013), pp...
[CML] AMN107 Can Produce Dramatic Results For CML PatientsRob Re: [CML] Early PCRURob [CML] Novartis PAP Helps Medicare PatientRob [CML] PCR AND BLOOD COUNTSICANDOALLTTC [CML] CML - The issue of heredityCheryl-Anne Simoneau [CML] Re: CML - The issue of hereditynissi6255 ...
"The second-generation CML drugs are more effective than imatinib and less toxic overall," said Hagop Kantarjian, M.D., professor and chair of The University of Texas MD Anderson Cancer Center's Department of Leukemia. Kantarjian is the corresponding author of the dasatinib study and co-author...